Drug quality analysis through high performance liquid chromatography of isometamidium chloride hydrochloride and diminazene diaceturate purchased from official and unofficial sources in Northern Togo

E. Tchamdja¹, A. E. Kulo², K. Akoda³, A. Teko-Agbo³, A. M. Assoumy³, E.M.M. Niang³, K. Batawui¹, K. Adomefa¹, A. A. Bankolé¹, K. Kombiagou¹, A. Hoppenheit^{4,*}, P. H. Clausen⁴, R. C. Mattioli⁵, R. Peter⁶, G. B. Napier⁶, R. De Deken⁷, T. Marcotty⁸, J. Van Den Abbeele⁹, V. Delespaux^{9, 10, *}

¹Direction de l'Elevage, Lomé, BP 4041 Togo,

²Ecole Supérieure d'Agronomie. Université de Lomé. BP 1515, Lomé, Togo

³Ecole Inter-Etats des Sciences et Médecine Vétérinaires de Dakar, Département de Santé Publique-Environnement, Service de Pharmacie-Toxicologie, BP 5077 Dakar-Fann, Sénégal

⁴Freie Universitaet Berlin, Institute for Parasitology and Tropical Veterinary Medicine, Robert-von-Ostertagstraße. 7-13, 14163 Berlin, Germany

⁵Food and Agriculture Organization of the United Nations, Viale delle Terme di Caracalla, 00153 Rome, Italy

⁶Global Alliance for Livestock Veterinary Medicines (GALVmed), Doherty Building, Pentlands Science Park, Bush Loan, Edinburgh EH26 0PZ, UK

⁷Institute of Tropical Medicine, Biomedical Sciences Department, Vector Biology, Veterinary Entomology, Nationalestraat 155, B-2000 Antwerp, Belgium

20 ⁸Veterinary Epidemiology, Risk-analysis and Diagnosis Research & Development, VERDI -
21 R&D (asbl), Rue du gravier, 7, B-4141 Louveigné, Belgium.

22 ⁹Institute of Tropical Medicine, Biomedical Sciences Department, Systems Biology,
23 Nationalestraat 155, B-2000 Antwerp, Belgium

24 ¹⁰Vrije Universiteit Brussel, Faculty of Sciences, Bio-engineering Department, Molecular
25 Biology, Pleinlaan 2, B-1050 Brussel, Belgium

26

27 **Abstract**

28 Trypanocidal drugs remain the most accessible and thus commonly used means of
29 controlling tsetse transmitted animal African trypanosomosis. In Togo, trypanocides are sold
30 on official as well as unofficial markets, but the quality of these trypanocides is
31 undocumented so a drug quality assessment study was conducted from May 2013 to June
32 2014. Trypanocides supplied by European, Indian and Chinese pharmaceutical companies
33 and sold on official and unofficial markets in Togo were purchased. In total fifty-two
34 trypanocides were obtained, 24 of these samples from official markets and 28 from
35 unofficial markets made up of a total of 36 diminazene diacetate and 16 isometamidium
36 chloride hydrochloride samples. The samples were analysed in the reference laboratory of
37 the OIE (World Organisation for Animal Health), Laboratory for the Control of Veterinary
38 Medicines (LACOMEV) in Dakar which uses galenic testing and high performance liquid
39 chromatography (HPLC) testing as standard reference analysis methods. The results
40 revealed a high proportion of trypanocides of sub-standard quality on the Togolese market:
41 40% were non-compliant to these quality reference standards. All of the HPLC non-
42 compliant samples contained lower amounts of active ingredient compared to the
43 concentration specified on the packaging. Non-compliance was higher in samples from the
44 unofficial (53.57%) than from the official markets (25%; $p=0.04$). The main drug
45 manufacturers, mostly of French origin in the study area, supply quality drugs through the
46 official legal distribution circuit. Products of other origins mostly found on illegal markets
47 present a significantly lower quality.

48 Key words: trypanocides, diminazene, isometamidium, drug quality, HPLC, Togo

49 * Corresponding author: Tel: +32 495 70 84 83 E-mail: Vincent.Delespaux@vub.ac.be

50 **Introduction**

51 Animal African trypanosomosis control is targeting either the vector or the parasite or both,
52 respectively. Despite the existence of ambitious programs in sub-Saharan Africa such as the
53 Pan African Tsetse and Trypanosomosis Eradication Campaign (PATTEC) and numerous
54 governmental initiatives in different countries to achieve elimination of the vector, tsetse
55 flies are still omnipresent. *Glossina* spp. are resilient vectors whose populations can restore
56 quickly after control operations cease. Even though many efficient techniques are available
57 for tsetse control, such as traps and targets (Esterhuizen et al., 2011), insecticide treated
58 cattle (Bauer et al., 1995; Vale et al., 1999; Shaw et al., 2015), ground/aerial spraying, and
59 sterile insect technique (Bouyer et al., 2014), elimination or even eradication of tsetse is
60 unlikely to succeed in the near future because such interventions must be tediously planned
61 at a continental scale in order to prevent tsetse re-infestation (Schofield and Kabayo, 2008).
62 This is not possible for small-scale livestock owners in tsetse-infested areas who rely on
63 access to trypanocidal drugs and self-organised or community-based vector control
64 activities to decrease the negative impacts of the disease on livestock production (Affognon
65 et al., 2010; Clausen et al., 2010; Muhanguzi et al., 2015). Ideally, trypanocidal drugs should
66 be limited to use in treating clinical cases but in areas with high cattle densities under tsetse
67 pressure, the restricted use of insecticides applied to the cattle's legs, lower belly, udder
68 and the perianal region offers a much higher cost/benefit ratio (Shaw et al., 2013, 2014,
69 2015). Despite this and increasing drug resistance, animal trypanosomosis are still largely
70 controlled by using trypanocides (Clausen et al., 2010; Mungube et al., 2012; Shaw et al.,
71 2015).

Three compounds are in use, either diminazene diaceturate (DA) as a curative treatment, or as prophylaxis both isometamidium chloride hydrochloride (ISM) and homidium salts (homidium bromide and homidium chloride ethanoate). However, the use of homidium salts is no longer advisable due to their mutagenic effects (Sutcliffe et al., 2014). Because of their extensive and wide-spread use, resistance to DA and ISM has been increasingly reported in African countries such as Togo (Delespaux et al., 2008; Tchamdja, 2013), and this threatens the sustainability of trypanosomosis prevention and control. The poor quality of these drugs is often cited as contributing to both the development and spread of trypanocidal drug resistance (Geerts et al., 2001; Grace, 2003; Clausen et al., 2010).

Studies conducted in 2003 in Togo and Benin (Teko-Agbo et al., 2003) and in 2007 in Senegal (Walbadet, 2007) showed that a high proportion of trypanocidal drugs circulating in the region were of poor quality. In 2013, the trypanocides DA and ISM accounted for the largest proportion of sales of veterinary medicines in Togo, at 38% of the 1.13 million euros declared in the official market (Kombiagou, 2013). This relatively high value trypanocide market encourages the maintenance of a large unofficial trade network, often operated by untrained people in weekly livestock or food markets, which in turn can lead to poor treatment outcomes if drugs are of sub-standard quality.

Experts agree that the use of sub-standard or counterfeit trypanocides has severe implications for animal health, public health and the local economy (Van Gool and Mattioli, 2009; Sutcliffe et al., 2014). Even though the true proportion of such medicines is difficult to ascertain at a global scale, some research indicates that substandard drugs are being sold in significant numbers, generating a multi-billion dollar industry. The International Federation

94 for Animal Health reports for example that the trade in unregistered and substandard
95 veterinary drugs is worth \$400 million annually (Kingsley, 2015). At the same time, a
96 sociological survey conducted in Nigeria states that farmers themselves identified poor
97 quality trypanocides as a negative impact on their livestock (Kingsley, 2015). Industry
98 representatives on the other hand emphasized that the large market for substandard or
99 fake products acted as a major disincentive for the development of new products, whereby
100 the direct damage of sub-standard drugs was held responsible for treatment failure
101 (Kingsley, 2015).

102 The objectives of this study were thus to assess the quality of trypanocidal drugs sold in
103 official and unofficial markets by different suppliers from different countries and to discuss
104 the results within the framework of the rules and regulations for veterinary pharmaceuticals
105 in Togo.

106 This study is part of a joint initiative for trypanocidal drug quality control in Africa whose
107 partners include the Global Alliance for Livestock Veterinary Medicines (GALVmed), the
108 Food and Agriculture Organization of United Nations (FAO), the International Federation of
109 Animal Health (IFAH), the International Atomic Energy Agency (IAEA) and the EC-funded
110 Trypanosomosis Rational Chemotherapy program (TRYRAC).

111 **Materials and Methods**

112 **Study site and period**

113 The study was conducted in Northern Togo in Kara and Savannah regions (figure 1), where
114 71% of the country's livestock production is concentrated (Ministère de l'Agriculture

115 Elevage et Pêche, 2013). Drugs were purchased from two wholesalers and from four
116 veterinary pharmacies, owned and run by veterinarians (official market) as well as from six
117 weekly markets (unofficial). The trypanocidal drugs were collected in May 2013 and
118 analysed at the Laboratory for the Control of Veterinary Medicines (LACOMEV) in Dakar,
119 Senegal from July 2013 until July 2014.

120 **Purchase of medicines**

121 The protocol for purchasing DA and ISM was developed by LACOMEV, one of the reference
122 laboratories of the World Animal Health Organisation (OIE). The products were purchased
123 from the sellers (official and unofficial) and then sealed in plastic bags identified by a unique
124 ID number. Information about (i) the trade name, (ii) the supplier, (iii) the place and date of
125 manufacture, (iv) the expiry date and finally (v) the place of purchase were recorded on a
126 standardised form.

127 To ensure sufficient sample quantity for analysis, 5 sachets of 10.5g and 10 sachets of 1.05g
128 as well as 5 sachets of 1g and 10 sachets of 125mg were purchased for each DA and ISM
129 sample, respectively.

130 In total, 52 samples (36 of DA and 16 of ISM) representing 25 different trade names were
131 purchased (24 and 28 from the official and unofficial market respectively), and analysed at
132 LACOMEV prior to the expiry date. The distribution of the samples according to active
133 ingredient and marketing channel (official versus unofficial) is provided in table 1.

134 **Identification and storage of samples**

135 The samples received at LACOMEV were entered into a Microsoft Access database.
136 Identification codes were assigned to each sample and samples were stored in the sample
137 laboratory where temperature is maintained at 22° +/- 2°C.

138 **Quality assessment**

139 Quality was assessed by (i) galenic tests, (ii) identification and (iii) measure of the
140 concentration of the active ingredient. The galenic test included pH measurement, the
141 solubility of ready-made solutions as well as solutions prepared from DA granules or ISM
142 powder according to the manufacturer's recommendations. The pH was measured using a
143 Mettler-Toledo MP 230 pH meter with a pH between 4 and 7 considered as compliant. The
144 solubility of solutions (ready-made or reconstituted) was assessed visually with the naked
145 eye for the absence of visible solid particles. Identification and concentration of the active
146 ingredient were assessed using high performance liquid chromatography (HPLC) according
147 to the OIE's monograph prepared by GALVmed, FAO and IFAH in collaboration with
148 Manchester Metropolitan University and IAEA (Sutcliffe et al., 2014). The reference
149 substances were provided to LACOMEV by the consortium GALVmed/FAO/IAEA/IFAH. The
150 reference substances for diminazene diaceturate (figure 2) and isometamidium chloride
151 hydrochloride (figure 3) (Igoli et al., 2014; Sutcliffe et al., 2014) were manufactured by
152 VETOQUINOL and CEVA, respectively. For DA, a measured concentration within $\pm 10\%$ of the
153 manufacturer's label claim was considered as compliant according to the threshold applied
154 by LACOMEV (Tetty et al., 2002). For ISM, the following criteria according OIE monograph
155 were used: (i) presence of the four isomers (I, II, III, IV), (ii) a proportion of isomer I (principal

156 component) equal to or greater than 55%, (iii) a proportion of isomers II, III and IV was equal
157 to or less than 40% and (iv) a proportion of the four isomers between 95-102%.
158 Pharmaceutical companies of the purchased test samples have been anonymised. Full
159 details about the HPLC method i.e. specificity, robustness, precision, linearity as well as the
160 limit of detection and quantification were described by Atsriku et al. (2002).

161 **Data analysis**

162 First, the binary compliance data was analysed in a logistic regression using drug (DA or
163 ISM), circuit (official or not) and the interaction between the two as explanatory variables.
164 To investigate the causes of the lack of compliance, the proportion of compliant samples
165 and exact 95% confidence intervals were calculated for the main manufacturers individually
166 and for the grouped smaller manufacturers (manufacturers with 1 or 2 samples only).
167 Finally, a backward stepwise logistic regression with origin (French, European or Asian), drug
168 (ISM and DA) and circuit (official or not) or seller (veterinary pharmacies, wholesalers or
169 unofficial as open markets) as explanatory variables was used to evaluate their respective
170 statistical significance.

Results

Only two samples, diminazene diaceturate samples, were non-compliant, based on the galenic test. HPLC analysis showed that all of the non-compliant trypanocides contained insufficient active ingredient. The proportions of compliant samples according to galenic testing, identification of the active ingredients and determination of their concentration are presented in table 1. The results showed that overall 40% were non-compliant; 50% for DA and 19% for ISM. In the official circuit, 25% of the samples were found non-compliant, whereas 54% of the drugs from illegal markets were non-compliant. The logistic regression using the drug (ISM or DA), the distribution circuit (official or unofficial) and the interaction between the two revealed no statistical effect of the drug (figure 4). Using the distribution circuits (official or not) as only explanatory variable, it appeared that a significant higher proportion of drugs distributed in unofficial markets were non-compliant ($p=0.04$). This is particularly true for DA (64% vs 19% in official circuit; $p=0.05$).

The 52 samples were produced by a total of 16 manufacturers. Most samples were produced by five of them (4 to 10 samples from each) whereas 14 samples were produced by 11 other companies. Figure 5 displays the proportions of non-compliant samples for the main manufacturers and the 95% confidence intervals.

Most of the brands of the 52 samples were supplied by French companies (32). Other countries of origin included India (11), Holland (2), Belgium (2), Spain (2), UK (2) and China (1). For further analysis, samples were grouped as French samples (32), samples of other origin (8) or Asian samples (12). In a backward stepwise logistic regression using origin (French, European or Asian), drug (ISM and DA) and circuit (official or not) or seller

(veterinary pharmacy, wholesaler or unofficial) as explanatory variables, France was the only significant variable with $p < 0.1$ ($p < 0.001$; $p = 0.001$ for DA on its own). A total of 82% of the French samples met the quality standards (95% CI: 57 – 94%) while 13% (95% CI: 2 – 54%) and 27% (95% CI: 9 – 59%) of other European and Asian samples were compliant, respectively.

Collinearity was observed between countries of origin and distribution circuits (table 2). Whereas French and Asian drugs are distributed in equivalent quantities through unofficial channels (44 and 50% respectively), drugs of European origin other than French were only found in open markets (unofficial circuit).

Non-compliance at different thresholds

The proportions of non-compliant samples were computed using different thresholds of percentage deviance from stated amounts of active ingredients. Increasing thresholds of +/- 5, 10, 15 and 20% gave non-compliance results of 46; 40; 19 and 10 % respectively.

Discussion

Overall results and study limitations

Quality assessment of trypanocides is a prerequisite to ensure good quality drugs for the management of trypanosomoses and the prevention of drug resistance (Clausen et al., 2010). This study focused on the identification of the active ingredients, the determination of their concentration, galenic testing of solubility and pH testing of the reconstituted solutions but the assessment of contaminants, impurities and/or degradation products was not performed. However, since this study did not verify the authenticity of samples, as

214 LACOMEV did not have samples of packaging from pharmaceutical companies for
215 comparison, the place of manufacture and the name of the supplier were simply recorded
216 from the packaging.

217 Results for non-compliance depended on the threshold that is used. The threshold
218 recommended by OIE for DA is $\pm 5\%$ (Sutcliffe et al., 2014). However, for purposes of
219 comparison with previous studies conducted by LACOMEV we used the threshold of $\pm$
220 10%. This threshold is the current standard applied by LACOMEV and is based on studies of
221 Tetey et al.(2002). In this work the rate of non-compliance for the tested 52 samples was
222 40% using the threshold of $\pm 10\%$. Obviously, this rate would increase to 46% if the OIE
223 threshold of $\pm 5\%$ had been used. Thresholds of $\pm 20\%$, classified as extremely deviating
224 by the World Health Organization in a study on anti-malarial medicine (World Health
225 Organization, 2011) would have resulted in this case of an only 10% non-compliance.

226 The rate of non-compliant trypanocides of 40% in this study is well below the detected 71%
227 in Ivory Coast (Assoumy et al., 2010), 100% in Cameroon (Teko-Agbo et al., 2009) and 70% in
228 Senegal (Akoda et al., 2008). However, it is equivalent to the level of 42% which was
229 observed in Burkina Faso by Teko-Agbo et al. (2011). This study provides information about
230 the quality of trypanocidal drugs available to farmers in Togo but it is not really possible to
231 link non-compliance to the quality of the original product or to poor conditions of storage
232 leading to a chemical degradation. All of the trypanocides that qualified as non-compliant by
233 HPLC analysis contained less active ingredient than indicated. The result is particularly
234 concerning in a country where resistance to DA and ISM has been detected (Tchamdja,

2013) and where the development of resistance is very likely being linked to under-dosing (Grace, 2003).

Non-compliance according to active ingredient

In total, DA samples showed greater non-compliance (50%) than ISM samples (19%). This high proportion of non-compliance for DA could be explained by the fact that the molecule is easier to synthesize, has a larger market and is therefore produced by several companies. This explains the wide range of sources for products containing DA compared to ISM which in turn increases the probability of poor quality and even falsification.

Non-compliance related to the marketing channel

Surprisingly, non-compliant trypanocides in Togo were found in both the official (25%) and unofficial markets (54%). The same observations have been made in studies in Burkina Faso (42 % / 43%) Cameroon (100 % / 100 %), Ivory Coast (46 % / 30 %) and Senegal (60 % / 80 %) for the official and unofficial markets, respectively (Akoda et al., 2008; Assoumy et al., 2010; Teko-Agbo et al., 2011, 2009). It is unlikely that the 54% of non-compliance observed within the unofficial market is solely due to poor conditions of storage, transport and/or handling. This situation is more likely to be linked to the source of supply and to a lack of quality control during manufacture. In addition to the poor quality of trypanocides, these medicines are often administered by untrained livestock keepers who may not accurately measure the weight of their cattle when treating and will thus fail to administer correct dosages as described Grace et al. (2008). Prices of trypanocides sold on unofficial markets are considerably lower than those from the official sector which may encourage livestock

256 keepers to buy these products. The problem is complicated by the fact that people who
257 illegally practice veterinary medicine often act as trypanocide wholesalers bringing even
258 more confusion about what is official and what is not (Pissang and Faye, 2012; Hoppenheit
259 et al., 2014). This results in reduced drug efficacy, poor treatment outcomes, increased drug
260 resistance and thereby negatively impact the livestock economy in Togo.

261 **Non-compliance according to supplier's company and country**

262 When looking at the results for compliance assorted by places of origin of the supplier,
263 products from Asian companies were significantly more likely to be non-compliant (75%)
264 compared to those from France (14%). For both countries, the proportions of samples
265 collected from the unofficial and official sectors were similar (50 and 44% unofficial from
266 Asia and France respectively). Trypanocides supplied by other companies (Holland, Belgium,
267 Spain, UK and China) were all found and purchased from the unofficial market and were
268 mostly non-compliant.

269 Comparable results were demonstrated in a study of anti-malarial medicine in six African
270 countries. Among products that were imported from China, India, Vietnam and Bangladesh,
271 the rates of non-compliance were 24, 33, 50 and 100% respectively compared to 2% in
272 medicines that were imported from South Africa and the United States (World Health
273 Organization, 2011). All of the brand names were anonymised in this study but the
274 respective companies will be contacted individually to inform them about the outcomes of
275 these quality tests.

276 **Non-compliant medicines and veterinary pharmaceutical legislations in Togo**

277 Togo has established a legal framework to resolve the problem of unregulated trade in
278 veterinary medicines, including trypanocides: a law, a decree and two orders dictate the
279 importation and supply of veterinary medicines (Ministère de l'Agriculture Elevage et Pêche,
280 1998, 2005, 2010, 2012). It is essential to effectively implement these rules and to raise
281 awareness among the principal stakeholders of the official and unofficial trade of veterinary
282 medicines in order to combat the high prevalence of poor quality trypanocides in Togo. It
283 will be necessary to thoroughly control unofficial trade and to enforce the quality control of
284 suppliers, ensuring that the trypanocides imported into Togo meet quality standards to
285 obtain a marketing authorisation from the West African Economic and Monetary Union
286 (UEMOA). Among the 25 analysed trypanocide brands, only five possessed a legal marketing
287 authorisation allowing their sale in Togo and in the UEMOA, all of which were manufactured
288 in France (UEMOA, 2012a, 2012b, 2012c, 2013a, 2013b). All five legally marketed brands
289 were compliant.

290 It is the responsibility of the relevant authorities in collaboration with the National
291 Association of Veterinarians in Togo to apply the legal framework for veterinary
292 pharmaceuticals in order to reduce illegal trade of poor quality veterinary medicines in Togo
293 because trypanocides of good quality are a prerequisite to control animal African
294 trypanosomosis and minimise the emergence of drug resistance (Clausen et al., 2010).

295 Registered veterinarians in Togo are mostly situated in the south of the country which is the
296 administrative centre, whereas the cattle population is concentrated in the northern regions
297 (Pissang and Faye, 2012; Hoppenheit et al., 2014). Thus, small-scale farmers are often

298 struggling to receive state of the art veterinary care for their animals which makes them
299 vulnerable to purchases of low priced and poor quality products on the unofficial market.
300 Only if the existing laws of Togo are enforced in the northern region, with for instance the
301 support of yet to be legalised animal health workers, will a reduction in poor quality
302 trypanocides in this market be addressed.

303 **Conclusions**

304 The main drug manufacturers, mostly of French origin in the study area, supply quality drugs
305 through a legal distribution circuit. Products of other origins mostly found on illegal markets
306 present a significantly lower quality. The results of this study on the quality of trypanocides
307 demonstrate a high proportion of non-compliant products used for the treatment of animal
308 African trypanosomosis. This non-compliance compromises the efficacy of the treatment as
309 well as boosts the development of drug resistance, which is already suspected to exist in
310 Togo (Tchamdja, 2013). The first step to the solution to this problem will be the
311 enforcement of national and sub-regional laws (UEMOA) on the quality control,
312 importation, supply and utilisation of veterinary medicines. Furthermore, high quality
313 veterinary products should not be in competition with products of unknown or sub-standard
314 quality. Low priced products will always be more attractive to cattle breeders with limited
315 financial resources but no way of reliably testing for quality and effectiveness. This is why it
316 is of utter importance to ensure a legal framework that is enforced, quality controlled and
317 supported by skilled veterinary personal at the field level in order to practice and
318 communicate state of the art veterinary care where it is needed most.

319 **Acknowledgements**

320 The authors thank the European Union and the associated project Trypanosomosis Rational
321 Chemotherapy (TRYRAC) as well as the Global Alliance for Livestock Veterinary Medicines
322 (GALVmed) supported by Bill & Melinda Gates Foundation and the UK Government's
323 Department for International Development (DFID), the Food and Agriculture Organization of
324 United Nations (FAO), the International Federation of Animal Health (IFAH), the
325 International Atomic Energy Agency (IAEA) for the establishment and quality control of the
326 LACOMEV laboratory. They also thank Anna Dean of the WHO for the improvement of the
327 language. Views reflected are solely of the authors.

328 **References**

- 329 Affognon, H., Randolph, T.F., Waibel, H., 2010. Economic analysis of animal disease control
330 inputs at farm level: the case of trypanocide use in villages under risk of drug resistance
331 in West Africa [WWW Document]. Livest. Res. Rural Dev. URL
332 <http://www.lrrd.org/lrrd22/12/affo22224.htm>
- 333 Akoda, K., Walbadet, L., Niang, E.M.M., Teko-Agbo, A., 2008. Qualité des médicaments
334 vétérinaires en circulation au Sénégal. Rev. Africaine Santé Prod. Anim. 6, 29–33.
- 335 Assoumy, A.M., Teko-Agbo, A., Akoda, K., Niang, E.M.M., Oulai, J., 2010. Qualité
336 pharmaceutique des médicaments vétérinaires en Côte d'Ivoire: cas du district
337 d'Abidjan. Rev. Africaine Santé Prod. Anim. 8, 149–153.
- 338 Atsriku, C., Watson, D.G., Tettey, J.N.A., Grant, M.H., Skellern, G.G., 2002. Determination of
339 diminazene aceturate in pharmaceutical formulations by HPLC and identification of
340 related substances by LC/MS. J. Pharm. Biomed. Anal. 30, 979–986. doi:10.1016/S0731-
341 7085(02)00450-8
- 342 Bauer, B., Amsler-Delafosse, S., Clausen, P.-H., Kabore, I., Petrich-Bauer, J., 1995. Successful
343 application of deltamethrin pour on to cattle in a campaign against tsetse flies
344 (*Glossina* spp) in the pastoral zone of Samorogouan, Burkina Faso. Trop. Med. Parasitol.
345 46, 183–189.
- 346 Bouyer, F., Seck, M.T., Dicko, A.H., Sall, B., Lo, M., Vreysen, M.J.B., Chia, E., Bouyer, J., Wane,
347 A., 2014. Ex-ante benefit-cost analysis of the elimination of a *Glossina palpalis*
348 *gambiensis* population in the Niayes of Senegal. PLoS Negl. Trop. Dis. 8, e3112.
349 doi:10.1371/journal.pntd.0003112
- 350 Clausen, P.-H., Bauer, B., Zessin, K.H., Diall, O., Bocoum, Z., Sidibe, I., Affognon, H., Waibel,
351 H., Grace, D., Randolph, T.F., 2010. Preventing and containing trypanocide resistance in
352 the cotton zone of West Africa. Transbound. Emerg. Dis. 57, 28–32.
- 353 Delespaulx, V., Geysen, D., Van den Bossche, P., Geerts, S., 2008. Molecular tools for the
354 rapid detection of drug resistance in animal trypanosomes. Trends Parasitol. 24, 236–
355 242.
- 356 Esterhuizen, J., Rayaisse, J.B., Tirados, I., Mpiana, S., Solano, P., Vale, G.A., Lehane, M.J.,
357 Torr, S.J., 2011. Improving the cost-effectiveness of visual devices for the control of
358 riverine tsetse flies, the major vectors of human African trypanosomiasis. PLoS Negl.
359 Trop. Dis. 5, e1257. doi:10.1371/journal.pntd.0001257.
360 doi:doi:10.1371/journal.pntd.0001257
- 361 Geerts, S., Holmes, P.H., Diall, O., Eisler, M.C., Holmes, P.H., Diall, O., Eisler, M.C., 2001.
362 African bovine trypanosomiasis: the problem of drug resistance. Trends Parasitol. 17,
363 18–21.
- 364 Grace, D., 2003. Rational drug use. To better manage trypanosomosis and trypanocide
365 resistance, Working pa. ed. International Livestock Research Institute, Nairobi, Kenya.
- 366 Grace, D., Randolph, T.F., Diall, O., Clausen, P.-H., 2008. Training farmers in rational drug-use

improves their management of cattle trypanosomosis: A cluster-randomised trial in south Mali. *Prev. Vet. Med.* 83, 83–97. doi:10.1016/j.prevetmed.2007.06.005

Hoppenheit, A., Bauer, B., Delespaulx, V., 2014. Fact Finding Mission to Togo, September 30-October 11 2013, EU-funded project: Trypanosomosis Rational Chemotherapy (TRYRAC), http://www.trypanocide.eu/partner-area/reports/mission-reports/Fact_Finding_Mission_Togo_FUB_2013.pdf [1.2 MB].

Igoli, J.O., Blackburn, G., Gray, A.I., Sutcliffe, O.B., Watson, D.G., Euerby, M.R., Skellern, G.G., 2014. Chromatographic and spectroscopic analysis of the components present in the phenanthridinium trypanocidal agent isometamidium. *Anal. Bioanal. Chem.* 407, 1171–1180. doi:10.1007/s00216-014-8337-z

Kingsley, P., 2015. Inscrutable medicines and marginal markets: tackling substandard veterinary drugs in Nigeria. *Pastoralism* 5, 2. doi:10.1186/s13570-014-0021-6

Kombiagou, K., 2013. Point sur les activités réalisées depuis 2010 (au Togo)., Séminaire régional des points focaux nationaux de l'OIE pour les produits vétérinaires. 3ème cycle. Maputo, Mozambique du 03 au 05 décembre (Communication power-point).

Ministère de l'Agriculture Elevage et Pêche, (MAEP), 2013. Profil de l'agriculture togolaise, in: 4ème Recensement National de L'agriculture 2011-2014. Ministère de l'Agriculture, de l'Elevage et de La Pêche(MAEP).Direction Des Statistiques Agricoles ,de l'Information et de La Documentation. p. 33.

Ministère de l'Agriculture Elevage et Pêche, (MAEP), 2012. Decret N°2012-015/PR du 04 avril 2012 portant réglementation de la pharmacie vétérinaire au Togo. Ministère l'Agriculture , l'Elevage la Pêche (MAEP)/Ministère la Santé (MS); Lomé-Togo 24 p.

Ministère de l'Agriculture Elevage et Pêche, (MAEP), 2010. Arrêté N°84/10/MAEP/cab/SG/DE du 24 septembre 2010 portant fixation des conditions d'importation et d'enlèvement des médicaments vétérinaires. Ministère l'Agriculture Elev. Pêche, (MAEP); Lomé-Togo 4 p.

Ministère de l'Agriculture Elevage et Pêche, (MAEP), 2005. ARRETE N°73 /MAEP/SG/DEP du 24 août 2005 fixant les conditions d'exercice de la profession de grossiste-répartiteur des produits vétérinaires. Ministère l'Agriculture Elev. Pêche, (MAEP); Lomé-Togo 4 p.

Ministère de l'Agriculture Elevage et Pêche, (MAEP), 1998. Loi N°98-019 du 23 décembre 1998 relative à l'exercice de la profession vétérinaire. *J. Off. la République Togol.* 33, 2–3.

Muhanguzi, D., Okello, W.O., Kabasa, J.D., Waiswa, C., Welburn, S.C., Shaw, A.P.M., 2015. Cost analysis of options for management of African Animal Trypanosomiasis using interventions targeted at cattle in Tororo District; south-eastern Uganda. *Parasit. Vectors* 8, 387. doi:10.1186/s13071-015-0998-8

Mungube, E.O., Vitouley, H.S., Allegye-Cudjoe, E., Diall, O., Boucoum, Z., Diarra, B., Sanogo, Y., Randolph, T.F., Bauer, B., Zessin, K.H., Clausen, P.-H., 2012. Detection of multiple drug-resistant *Trypanosoma congolense* populations in village cattle of south-east Mali. *Parasit. Vectors* 5, 155. doi:10.1186/1756-3305-5-155

407 Pissang, C., Faye, D., 2012. November 2012: Mission Togo VSF, EU-funded project:
 408 Trypanosomosis Rational Chemotherapy (TRYRAC),
 409 <http://www.trypanocide.eu/partner-area/reports/mission-reports/>, Nov2012
 410 Identification of Stakeholders.pdf [354.2 KB].

411 Schofield, C.J., Kabayo, J.P., 2008. Trypanosomiasis vector control in Africa and Latin
 412 America. *Parasit. Vectors* 1, 24. doi:10.1186/1756-3305-1-24

413 Shaw, A.P.M., Cecchi, G., Wint, G.R.W., Mattioli, R.C., Robinson, T.P., 2014. Mapping the
 414 economic benefits to livestock keepers from intervening against bovine
 415 trypanosomosis in Eastern Africa. *Prev. Vet. Med.* 113, 197–210.

416 Shaw, A.P.M., Torr, S.J., Waiswa, C., Cecchi, G., Wint, G.R.W., Mattioli, R.C., Robinson, T.P.,
 417 2013. Estimating the costs of tsetse control options: An example for Uganda. *Prev. Vet.*
 418 *Med.* 110, 290–303. doi:10.1016/j.prevetmed.2012.12.014

419 Shaw, A.P.M., Wint, G.R.W., Cecchi, G., Torr, S.J., Mattioli, R.C., Robinson, T.P., 2015.
 420 Mapping the benefit-cost ratios of interventions against bovine trypanosomosis in
 421 Eastern Africa. *Prev. Vet. Med.* 1–11. doi:10.1016/j.prevetmed.2015.06.013

422 Sutcliffe, O.B., Skellern, G.G., Araya, F., Cannavan, A., Sasanya, J.J., Dungu, B., Van Gool, F.,
 423 Münstermann, S., Mattioli, R.C., 2014. Animal trypanosomosis : making quality control
 424 of trypanocidal drugs possible. *Rev. Sci. Tech. Int. des Epizoot.* 33, 1–42.

425 Tchamdja, E., 2013. Etude de la prévalence des résistances aux trypanocides dans les
 426 régions de la Kara et des Savanes au Togo. *Rapp. terrain. Proj. TRYRAC-Togo.Direction*
 427 *l'Elevage*.

428 Teko-Agbo, A., Akoda, K., Assoumy, A.M., Kadja, M.C., Niang, E.M.M., Messomo Ndjana, F.,
 429 Walbadet, L., Abiola, F.A., 2009. Qualité des médicaments vétérinaires en circulation au
 430 Cameroun et au Sénégal. *Dakar Médical* 54, 226–234.

431 Teko-Agbo, A., Assoumy, A.M., Akoda, K., Niang, E.M.M., Badini, H., LJ, P., 2011. Qualité
 432 pharmaceutique des médicaments antiparasitaires vétérinaires au Burkina-Faso. *Rev.*
 433 *Africaine Santé Prod. Anim.* 9, 3–7.

434 Teko-Agbo, A., Biaou, F.C., Akoda, K., Faure, P., Abiola, F.A., 2003. Contrefaçons et
 435 malfaçons de trypanocides à base de diminazène et d'anthelminthiques contenant de
 436 l'albendazole au Benin et au Togo. *Rev. Africaine Santé Prod. Anim.* 1, 39–47.

437 Tettey, J.N.A., Astriku, C., Chizyuka, G., Slingenbergh, J., 2002. Non conformance of
 438 diminazene preparations to manufacturers' label claims: an extra factor in the
 439 development of chemoresistance? *News. Integr. Control Pathog. Trypanos. Vectors* 5,
 440 24–25.

441 UEMOA, 2013a. Décision N° 349 /2013/ PCOM/UEMOA du 27 novembre 2013 portant sur le
 442 transfert de l'autorisation de mise sur le marché pour le médicament vétérinaire
 443 INOMAZENE de la Société INOUKO GENERICS à la Société LAPROVET, La Commission de
 444 l'UEMOA, Ouagadougou-Burkina-Faso.

445 UEMOA, 2013b. Décision N°321/2013/PCOM/UEMOA du 07 novembre 2013 portant sur
 446 l'autorisation de mise sur le marché du médicament vétérinaire Securidium, La

447 Commission de l'UEMOA, Ouagadougou-Burkina-Faso.

448 UEMOA, 2012a. Décision N°0077/2012/PCOM/UEMOA du 30 avril 2012 portant sur
 449 l'autorisation de mise sur le marché de médicaments vétérinaires, La Commission de
 450 l'UEMOA, Ouagadougou-Burkina-Faso.

451 UEMOA, 2012b. Décision N°0082/2012/PCOM/UEMOA du 07 mai 2012 portant sur
 452 l'autorisation de mise sur le marché de médicaments vétérinaires, La Commission de
 453 l'UEMOA, Ouagadougou-Burkina-Faso.

454 UEMOA, 2012c. Décision N°0223/2012/PCOM/UEMOA du 23 octobre 2012 portant sur
 455 l'autorisation de mise sur le marché du médicament vétérinaire Trypamidum-Samorin,
 456 La Commission de l'UEMOA, Ouagadougou-Burkina-Faso.

457 Vale, G.A., Mutika, G., Lovemore, D.F., 1999. Insecticide-treated cattle for controlling tsetse
 458 flies (Diptera: *Glossinidae*): some questions answered, many posed. Bull. Entomol. Res.
 459 89, 569–578. doi:10.1017/S0007485399000723

460 Van Gool, F., Mattioli, R.C., 2009. Poor quality and fake trypanocidal drugs, a real threat for
 461 a sustainable and profitable livestock production in Sub-Sahara Africa, in: Proceeding
 462 of the 30th International Scientific Council for Trypanosomiasis Research and Control
 463 (ISCTRC).Kampala, Ouganda.

464 Walbadet, L., 2007. Etude de la distribution de la qualité des médicaments vétérinaires au
 465 sénégal: cas des régions de Dakar, Kaolack et Thiès. Thèse Dr. en médecine vétérinaire.
 466 Univ. Cheikh Anta Diop Dakar 120 p.

467 World Health Organization, 2011. Survey of the quality of selected antimalarial medicines
 468 circulating in six countries of sub-Saharan Africa.
 469 http://www.who.int/medicines/publications/WHO_QAMSA_report.pdf.

470

471 List of Figures

472 Figure 1: Sites of purchase of trypanocidal medicines in Northern Togo

473 Figure 2: Molecular structure of diminazene diaceturate (Sutcliffe et al., 2014)

474 Figure 3: Molecular structure of isometamidium chloride hydrochloride (Sutcliffe et al.,
475 2014)

476 Figure 4: Proportion of compliant samples in function of the drug (ISM or DA) and the
477 distribution circuit (official or not) with 95% confidence intervals

478 Figure 5: Proportion of non-compliant drugs by manufacturer with 95% confidence intervals

479 With A, B, C, D and E as anonymised pharmaceutical companies; others as grouped pharmaceutical companies

480

481 List of tables

482 Table 1: Proportion of compliant isometamidium chloride hydrochloride and diminazene
483 diaceturate drugs sampled from official and illegal outlets (number compliant / number
484 tested)

485 Table 2: Proportion of compliant isometamidium chloride hydrochloride and diminazene
486 diaceturate drugs according to regions of origin (number compliant / number tested)

487

TABLES

488 Table 1: Proportion of compliant ISM and DA drugs sampled from official and illegal outlets

489 (number compliant / number tested)

Compound	Official circuit		Open market (unofficial)	Total
	Pharmacy	Wholesaler		
ISM	5/6	3/4	5/6	13/16
DA	4/4	6/10	8/22	18/36
Total	9/10	9/14	13/28	31/52

490 Table 2: Proportion of compliant ISM and DA drugs according to regions of origin (number
 491 compliant / number tested)

Origin	Official circuit		Open market (unofficial)	Total
	Pharmacy	Wholesaler		
France	9 / 10	7 / 8	11 / 14	27 / 32
Europe	0 / 0	0 / 0	1 / 8	1 / 8
Asia	0 / 0	2 / 6	1 / 6	3 / 12
Total	9 / 10	9 / 14	13 / 28	31 / 52

Figure 1

FIGURES

Figure 2

Figure 3

	R^1	R^2	R^3	n
I	X	H	H	1
II	H	X	H	1
III	H	H	X	1
IV	X	X	H	2

X =

Figure 4

Figure 5